Quest Diagnostics Incorporated (DGX) Stock Analysis
Last updated Oct 27, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 75
- Profitability 60
- Business Quality 60
- Balance Sheet 55
- Cash Flow 80
Why this rating?
Health 67/100 — Good Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Quest Diagnostics Incorporated (DGX) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates Quest Diagnostics Incorporated 67/100 (Good Quality) due to solid business quality, steady revenue growth, and manageable leverage.
Investment profile
- Quality Moderate
- Growth Moderate
- Balance Sheet Adequate
- Valuation Fair
Financial highlights
Valuation
- P/E 25.75
- Forward P/E 20.23
- PEG 1.58
- EV/Revenue 2.76
Profitability
- Revenue Growth 10.0%
- Gross Margin 33.2%
- Operating Margin 15.6%
- Net Margin 9.5%
- ROE 15.3%
Financial strength
- Cash $797.00M
- Debt $6.40B
- Net Cash $-5.60B
- Free Cash Flow $1.36B
- Current Ratio 1.7
Similar companies
Peers in Diagnostics & Research, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Veracyte, Inc. Diagnostics & Research VCYT$50.28 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Good Entry Good EntryA usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
- Illumina, Inc. Diagnostics & Research ILMN$279.47 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- CareDx, Inc. Diagnostics & Research CDNA$70.53 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Qiagen N.V. Diagnostics & Research QGEN$50.17 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Danaher Corporation Diagnostics & Research DHR$232.00 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Sotera Health Company Diagnostics & Research SHC$18.49 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Revvity, Inc. Diagnostics & Research RVTY$161.86 66 Health 66 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- BillionToOne, Inc. Diagnostics & Research BLLN$114.07 65 Health 65 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Quest Diagnostics Incorporated (DGX).